ReviewTrends in cancer2017
Cohesin Mutations in Myeloid Malignancies.
Review in Trends in cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 45 citations in OpenAlex.
- AML Disparities Across Racial Ancestry Groups: A Spotlight on the NPM1 Mutations.International journal of molecular sciences · 2026Review
- Cohesin mutations in acute myeloid leukemia.Leukemia · 2024Review
- 3C methods in cancer research: recent advances and future prospects.Experimental & molecular medicine · 2024Review
- Cohesin regulates alternative splicing.Science advances · 2023Article
- Combinatorial genetics reveals the Dock1-Rac2 axis as a potential target for the treatment of NPM1;Cohesin mutated AML.Leukemia · 2022Article
- In Pursuit of Genetic Prognostic Factors and Treatment Approaches in Secondary Acute Myeloid Leukemia-A Narrative Review of Current Knowledge.Journal of clinical medicine · 2022Review
- 3D chromatin architecture and transcription regulation in cancer.Journal of hematology & oncology · 2022Review
- MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies.Journal of hematology & oncology · 2021Review
- Sister chromatid cohesion defects are associated with chromosomal copy number heterogeneity in high hyperdiploid childhood acute lymphoblastic leukemia.Genes, chromosomes & cancer · 2021Article
- Increased risk of leukaemia in children with Down syndrome: a somatic evolutionary view.Expert reviews in molecular medicine · 2021Article
- DOT1L inhibitors block abnormal self-renewal induced by cohesin loss.Scientific reports · 2021Article
- A cohesin cancer mutation reveals a role for the hinge domain in genome organization and gene expression.PLoS genetics · 2021Article
- A cohesive look at leukemogenesis: The cohesin complex and other driving mutations in AML.Neoplasia (New York, N.Y.) · 2021Review
- Mouse Models of Myeloid Malignancies.Cold Spring Harbor perspectives in medicine · 2021Review
- Super-Enhancers and CTCF in Early Embryonic Cell Fate Decisions.Frontiers in cell and developmental biology · 2021Review
- Topologically Associating Domains and Regulatory Landscapes in Development, Evolution and Disease.Frontiers in cell and developmental biology · 2021Review
- Review
- Review
- Chronic loss of STAG2 leads to altered chromatin structure contributing to de-regulated transcription in AML.Journal of translational medicine · 2020Article
- Acute Megakaryocytic Leukemia.Cold Spring Harbor perspectives in medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
Acute Myeloid Leukemia (AML) is a hematologic malignancy with a poor prognosis. Recent genome-wide sequencing studies have identified frequent mutations in genes encoding members of the cohesin complex. Mutations in cohesin contribute to myeloid malignancies by conferring enhanced self-renewal of hematopoietic stem and progenitor cells but the mechanisms behind this phenotype have not been fully elucidated. Of note, cohesin mutations are highly prevalent in acute megakaryocytic leukemia associated with Down syndrome (DS-AMKL), where they occur in over half of patients. Evidence suggests that cohesin mutations alter gene expression through changes in chromatin accessibility and/or aberrant targeting of epigenetic complexes. In this review we discuss the pathogenic mechanisms by which cohesin mutations contribute to myeloid malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.